Pareto: Vicore Pharma Superior Clinical data vs Competion means Vicore Will Gain a Significant Attention. Confrence on 4/9/22 Could be the Catalyst Point

We have several pharma investments. One of the largest is our Vicore position. It is one of the most interesting plays according to Pareto analyst. I enclose summary of the Pareto note from this morning.

Vicore is below radar screens of many investors. The upcoming 4 September conference, which is the major event of the year for Vicore field, could be a turning point for Vicore. Pareto analyst: “With this upcoming event, clearly superior clinical data vs. the competition, we believe Vicore Pharma will gain significant attention.

IPF data to be presented alongside competitors at conference

Vicore Pharma today announced that the interim data in IPF will be presented at the European Respiratory Society (ERS) congress in Barcelona on September 4, 15:00 CET.

On the same day, (previously published) data from Boehringer Ingelheim and Pliant Therapeutics will be presented. Best data reported from Boehringer’s BI 1015550 to date, is a mean increase in forced vital capacity (FVC) of +5.7 mL after 12 weeks.

Best data reported from Pliant Therapeutics’ PLN-74809 to date, is a mean increase in FVC of +24.6 mL after 12 weeks (only one group, rest experienced declines in FVC). 

As a reminder, Vicore’s C21 IPF data included not just longer & thus more robust follow-ups (24 & 36 weeks) which showed a trajectory, it also reported much higher mean increases in FVC with +251 mL at week24 and +751mL at week 36. 

From our study of IPF related FVC measurements, we would consider short term changes in the range of +/- 50-70 mL as within the variability of these measurements.

With this upcoming event, clearly superior clinical data vs. the competition, we believe Vicore Pharma will gain significant attention. Further, we believe that it is possible (due to time passed since last follow-up), that Vicore will release new clinical data from its IPF trial in the coming 1-3 weeks, which we expect to be a major catalyst by itself.

We reiterate our Buy rating on VICO with a target price of SEK 97/share. 

Our other pharma positions include Biovica, Bioinvent, Eigr, Sedana and Calliditas. We wrote here several times on those opportunities.

Biovica, that recently obtained FDA approval for its innovative breast cancer test will be presenting to investors their product lunch strategy. See


The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice. Please do your own research before making any investment action.

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Leave a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s